Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside

PL Capital believes the company is well positioned to benefit from increasing pharmaceutical outsourcing, a deep commercial pipeline and capacity expansion

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to livemint.com's own reporting rather than reproducing it — the excerpt above comes from livemint.com's own feed.